Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2018-12-14

AUTHORS

Yuko Asai, Hideki Sano, Makoto Miyazaki, Mika Iwakura, Yoshikazu Maeda, Mitsuyoshi Hara

ABSTRACT

BACKGROUND: We report on the results of a Japanese postmarketing drug-use survey of suvorexant (Belsomra®) tablets. METHODS: A survey with a ≤ 6-month observation period after the start of administration was conducted, targeting insomnia patients who were treated with suvorexant for the first time in Japan. Information on the safety and efficacy of the drug product was collected. The evaluation period was July 21, 2015-August 12, 2017, and the target number of patients was 3428. RESULTS: The mean administration period for the safety analysis population of 3248 patients was 113 days. At 6 months after the start of treatment, 48.6% (1577/3248) of the patients had been continually receiving treatment, and 51.4% (1671/3248) of the patients discontinued/dropped out of treatment before 6 months. Among the patients who discontinued/dropped out of the treatment, more than 30% discontinued due to improvement. The mean treatment duration for those who had discontinued treatment for this reason was 62 days. The incidence rate of adverse drug reactions among those in the safety analysis population was 9.7%, and the common adverse drug reactions were somnolence (3.6%), insomnia (1.2%), dizziness (1.1%), and nightmare (0.8%), all of which are described in the product label. No additional noteworthy events were observed. In 2439 patients with a final overall global assessment of sleep judged by physicians, the 'improved' rate was 74.0%. Among 2424 patients who provided a final overall global assessment, the improvement rate was 73.2%, which was comparable with the improvement rate judged by physicians. Regarding clinical effects (based on patient diary data or physician's assessment), reduction in median sleep latency and increase in median total sleep time (reduction from 60 to 50 min and increase from 300 to 360 min compared with baseline, respectively) were observed at 1 week after the start of treatment and onwards, and the effect was maintained after the start of treatment for 6 months. A similar effect was observed irrespective of age groups or reasons for using suvorexant. CONCLUSION: This survey was an exploratory observational study without a control group; the interpretation of results may require the consideration of factors that may have caused bias in the results, such as demographic characteristics and effects of other drugs. However, the results suggest that suvorexant can be a useful drug in daily clinical practice for treating insomnia. More... »

PAGES

27-46

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s40268-018-0256-6

DOI

http://dx.doi.org/10.1007/s40268-018-0256-6

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1110639167

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30552562


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1117", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Public Health and Health Services", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azepines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Utilization Review", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Japan", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sleep Aids, Pharmaceutical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sleep Initiation and Maintenance Disorders", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sleep Latency", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Surveys and Questionnaires", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tablets", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Triazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pharmacovigilance, MSD K.K., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.473495.8", 
          "name": [
            "Pharmacovigilance, MSD K.K., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Asai", 
        "givenName": "Yuko", 
        "id": "sg:person.014560111250.07", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014560111250.07"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Neuropsychiatry, Medical Information, Medical Affairs, MSD K.K., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.473495.8", 
          "name": [
            "Neuropsychiatry, Medical Information, Medical Affairs, MSD K.K., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Sano", 
        "givenName": "Hideki", 
        "id": "sg:person.07546306573.76", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07546306573.76"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmacovigilance, MSD K.K., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.473495.8", 
          "name": [
            "Pharmacovigilance, MSD K.K., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Miyazaki", 
        "givenName": "Makoto", 
        "id": "sg:person.013165150250.11", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013165150250.11"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmacovigilance, MSD K.K., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.473495.8", 
          "name": [
            "Pharmacovigilance, MSD K.K., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwakura", 
        "givenName": "Mika", 
        "id": "sg:person.016153052250.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016153052250.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmacovigilance, MSD K.K., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.473495.8", 
          "name": [
            "Pharmacovigilance, MSD K.K., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maeda", 
        "givenName": "Yoshikazu", 
        "id": "sg:person.016060561550.39", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016060561550.39"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmacovigilance, MSD K.K., Tokyo, Japan", 
          "id": "http://www.grid.ac/institutes/grid.473495.8", 
          "name": [
            "Pharmacovigilance, MSD K.K., Tokyo, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Hara", 
        "givenName": "Mitsuyoshi", 
        "id": "sg:person.010245361450.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010245361450.00"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2018-12-14", 
    "datePublishedReg": "2018-12-14", 
    "description": "BACKGROUND: We report on the results of a Japanese postmarketing drug-use survey of suvorexant (Belsomra\u00ae) tablets.\nMETHODS: A survey with a \u2264\u20096-month observation period after the start of administration was conducted, targeting insomnia patients who were treated with suvorexant for the first time in Japan. Information on the safety and efficacy of the drug product was collected. The evaluation period was July 21, 2015-August 12, 2017, and the target number of patients was 3428.\nRESULTS: The mean administration period for the safety analysis population of 3248 patients was 113\u00a0days. At 6\u00a0months after the start of treatment, 48.6% (1577/3248) of the patients had been continually receiving treatment, and 51.4% (1671/3248) of the patients discontinued/dropped out of treatment before 6\u00a0months. Among the patients who discontinued/dropped out of the treatment, more than 30% discontinued due to improvement. The mean treatment duration for those who had discontinued treatment for this reason was 62\u00a0days. The incidence rate of adverse drug reactions among those in the safety analysis population was 9.7%, and the common adverse drug reactions were somnolence (3.6%), insomnia (1.2%), dizziness (1.1%), and nightmare (0.8%), all of which are described in the product label. No additional noteworthy events were observed. In 2439 patients with a final overall global assessment of sleep judged by physicians, the 'improved' rate was 74.0%. Among 2424 patients who provided a final overall global assessment, the improvement rate was 73.2%, which was comparable with the improvement rate judged by physicians. Regarding clinical effects (based on patient diary data or physician's assessment), reduction in median sleep latency and increase in median total sleep time (reduction from 60 to 50\u00a0min and increase from 300 to 360\u00a0min compared with baseline, respectively) were observed at 1 week after the start of treatment and onwards, and the effect was maintained after the start of treatment for 6\u00a0months. A similar effect was observed irrespective of age groups or reasons for using suvorexant.\nCONCLUSION: This survey was an exploratory observational study without a control group; the interpretation of results may require the consideration of factors that may have caused bias in the results, such as demographic characteristics and effects of other drugs. However, the results suggest that suvorexant can be a useful drug in daily clinical practice for treating insomnia.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s40268-018-0256-6", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1020803", 
        "issn": [
          "1174-5886", 
          "1179-6901"
        ], 
        "name": "Drugs in R&D", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "19"
      }
    ], 
    "keywords": [
      "start of treatment", 
      "safety analysis population", 
      "adverse drug reactions", 
      "overall global assessment", 
      "analysis population", 
      "drug reactions", 
      "common adverse drug reactions", 
      "global assessment", 
      "improvement rate", 
      "mean administration period", 
      "median sleep latency", 
      "mean treatment duration", 
      "start of administration", 
      "median total sleep time", 
      "daily clinical practice", 
      "total sleep time", 
      "exploratory observational study", 
      "clinical effects", 
      "administration period", 
      "incidence rate", 
      "sleep latency", 
      "insomnia patients", 
      "observational study", 
      "useful drug", 
      "patients", 
      "treatment duration", 
      "Drug Use Survey", 
      "sleep time", 
      "clinical practice", 
      "control group", 
      "age groups", 
      "observation period", 
      "suvorexant", 
      "demographic characteristics", 
      "months", 
      "treatment", 
      "insomnia", 
      "evaluation period", 
      "physicians", 
      "product labels", 
      "similar effects", 
      "Results Surveys", 
      "drugs", 
      "consideration of factors", 
      "days", 
      "interpretation of results", 
      "somnolence", 
      "dizziness", 
      "group", 
      "population", 
      "period", 
      "start", 
      "drug products", 
      "sleep", 
      "administration", 
      "weeks", 
      "efficacy", 
      "assessment", 
      "rate", 
      "effect", 
      "survey", 
      "duration", 
      "target number", 
      "safety", 
      "latency", 
      "tablets", 
      "nightmares", 
      "factors", 
      "study", 
      "results", 
      "reasons", 
      "time", 
      "events", 
      "reduction", 
      "improvement", 
      "first time", 
      "practice", 
      "reaction", 
      "number", 
      "bias", 
      "Japan", 
      "characteristics", 
      "information", 
      "labels", 
      "consideration", 
      "products", 
      "interpretation", 
      "noteworthy events", 
      "suvorexant (Belsomra\u00ae) tablets", 
      "additional noteworthy events", 
      "final overall global assessment", 
      "Japanese Drug-Use Results Survey", 
      "Drug-Use Results Survey"
    ], 
    "name": "Suvorexant (Belsomra\u00ae Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey", 
    "pagination": "27-46", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1110639167"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s40268-018-0256-6"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30552562"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s40268-018-0256-6", 
      "https://app.dimensions.ai/details/publication/pub.1110639167"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-12-01T19:42", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211201/entities/gbq_results/article/article_793.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s40268-018-0256-6"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0256-6'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0256-6'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0256-6'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s40268-018-0256-6'


 

This table displays all metadata directly associated to this object as RDF triples.

268 TRIPLES      21 PREDICATES      138 URIs      129 LITERALS      25 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s40268-018-0256-6 schema:about N017f379102364756b32dff09172b0463
2 N0bab071d59ba41a69a6d2931f03ffa2d
3 N1033b0bf5dd04f1682a98856d2eda805
4 N2eb4efe02e9d4a2190a398098e7e3168
5 N337eb056b1e84430a3c198002b6410ef
6 N4f5fb930eac544e4963c38bba7588e63
7 N5a287b1f975543f0ae33faa927f6a832
8 N70690f84096c4ae6af0940cc6d42805c
9 N79de78b8f5b244049456f0ae4b2a372d
10 N7e319f445f7b4b8992a700d104ce5c39
11 N92b3add168f14889ab6c5e35371f1451
12 N962664f213c149ecbd9ac65e6251515a
13 N96c0541326c649a7b5dc0d00f73e1362
14 N986b268aad8e49a39b9789a538ccf7c2
15 Na4c522335eef4d958960110caef947b1
16 Ndc282c28289e46adada8d9fbcdb4f607
17 Ndfc1dd7a1e444e8e9395d92aa880f621
18 Nf0c35db6c7c142749f2437aa1d28c3b2
19 anzsrc-for:11
20 anzsrc-for:1103
21 anzsrc-for:1117
22 schema:author Nec4c3d96086c45119972c2713b4f3fcc
23 schema:datePublished 2018-12-14
24 schema:datePublishedReg 2018-12-14
25 schema:description BACKGROUND: We report on the results of a Japanese postmarketing drug-use survey of suvorexant (Belsomra<sup>®</sup>) tablets. METHODS: A survey with a ≤ 6-month observation period after the start of administration was conducted, targeting insomnia patients who were treated with suvorexant for the first time in Japan. Information on the safety and efficacy of the drug product was collected. The evaluation period was July 21, 2015-August 12, 2017, and the target number of patients was 3428. RESULTS: The mean administration period for the safety analysis population of 3248 patients was 113 days. At 6 months after the start of treatment, 48.6% (1577/3248) of the patients had been continually receiving treatment, and 51.4% (1671/3248) of the patients discontinued/dropped out of treatment before 6 months. Among the patients who discontinued/dropped out of the treatment, more than 30% discontinued due to improvement. The mean treatment duration for those who had discontinued treatment for this reason was 62 days. The incidence rate of adverse drug reactions among those in the safety analysis population was 9.7%, and the common adverse drug reactions were somnolence (3.6%), insomnia (1.2%), dizziness (1.1%), and nightmare (0.8%), all of which are described in the product label. No additional noteworthy events were observed. In 2439 patients with a final overall global assessment of sleep judged by physicians, the 'improved' rate was 74.0%. Among 2424 patients who provided a final overall global assessment, the improvement rate was 73.2%, which was comparable with the improvement rate judged by physicians. Regarding clinical effects (based on patient diary data or physician's assessment), reduction in median sleep latency and increase in median total sleep time (reduction from 60 to 50 min and increase from 300 to 360 min compared with baseline, respectively) were observed at 1 week after the start of treatment and onwards, and the effect was maintained after the start of treatment for 6 months. A similar effect was observed irrespective of age groups or reasons for using suvorexant. CONCLUSION: This survey was an exploratory observational study without a control group; the interpretation of results may require the consideration of factors that may have caused bias in the results, such as demographic characteristics and effects of other drugs. However, the results suggest that suvorexant can be a useful drug in daily clinical practice for treating insomnia.
26 schema:genre article
27 schema:inLanguage en
28 schema:isAccessibleForFree true
29 schema:isPartOf N9b207271b7f0421689ece24329dc219a
30 Ne3c2ef4ee0d14096b3e57e5b4c99bb32
31 sg:journal.1020803
32 schema:keywords Drug Use Survey
33 Drug-Use Results Survey
34 Japan
35 Japanese Drug-Use Results Survey
36 Results Surveys
37 additional noteworthy events
38 administration
39 administration period
40 adverse drug reactions
41 age groups
42 analysis population
43 assessment
44 bias
45 characteristics
46 clinical effects
47 clinical practice
48 common adverse drug reactions
49 consideration
50 consideration of factors
51 control group
52 daily clinical practice
53 days
54 demographic characteristics
55 dizziness
56 drug products
57 drug reactions
58 drugs
59 duration
60 effect
61 efficacy
62 evaluation period
63 events
64 exploratory observational study
65 factors
66 final overall global assessment
67 first time
68 global assessment
69 group
70 improvement
71 improvement rate
72 incidence rate
73 information
74 insomnia
75 insomnia patients
76 interpretation
77 interpretation of results
78 labels
79 latency
80 mean administration period
81 mean treatment duration
82 median sleep latency
83 median total sleep time
84 months
85 nightmares
86 noteworthy events
87 number
88 observation period
89 observational study
90 overall global assessment
91 patients
92 period
93 physicians
94 population
95 practice
96 product labels
97 products
98 rate
99 reaction
100 reasons
101 reduction
102 results
103 safety
104 safety analysis population
105 similar effects
106 sleep
107 sleep latency
108 sleep time
109 somnolence
110 start
111 start of administration
112 start of treatment
113 study
114 survey
115 suvorexant
116 suvorexant (Belsomra<sup>®</sup>) tablets
117 tablets
118 target number
119 time
120 total sleep time
121 treatment
122 treatment duration
123 useful drug
124 weeks
125 schema:name Suvorexant (Belsomra® Tablets 10, 15, and 20 mg): Japanese Drug-Use Results Survey
126 schema:pagination 27-46
127 schema:productId N04273fb3a94f4a3b865c707384c19562
128 Ne0de215c486c464698d437aa7b950f48
129 Nfb973909dd0c4f658e58b39895d181e7
130 schema:sameAs https://app.dimensions.ai/details/publication/pub.1110639167
131 https://doi.org/10.1007/s40268-018-0256-6
132 schema:sdDatePublished 2021-12-01T19:42
133 schema:sdLicense https://scigraph.springernature.com/explorer/license/
134 schema:sdPublisher N7fa924a4f00a49e898c44c3dfb0ae0c0
135 schema:url https://doi.org/10.1007/s40268-018-0256-6
136 sgo:license sg:explorer/license/
137 sgo:sdDataset articles
138 rdf:type schema:ScholarlyArticle
139 N017f379102364756b32dff09172b0463 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Surveys and Questionnaires
141 rdf:type schema:DefinedTerm
142 N04273fb3a94f4a3b865c707384c19562 schema:name pubmed_id
143 schema:value 30552562
144 rdf:type schema:PropertyValue
145 N0bab071d59ba41a69a6d2931f03ffa2d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Adolescent
147 rdf:type schema:DefinedTerm
148 N1033b0bf5dd04f1682a98856d2eda805 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Sleep Initiation and Maintenance Disorders
150 rdf:type schema:DefinedTerm
151 N2eb4efe02e9d4a2190a398098e7e3168 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Aged, 80 and over
153 rdf:type schema:DefinedTerm
154 N337eb056b1e84430a3c198002b6410ef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Azepines
156 rdf:type schema:DefinedTerm
157 N39353125415947d0aa8e387f1bb86fcd rdf:first sg:person.016153052250.08
158 rdf:rest Nfdd560171469486eb4a5350138f002fa
159 N4f5fb930eac544e4963c38bba7588e63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Tablets
161 rdf:type schema:DefinedTerm
162 N54ab11c585a445d3bed90d066e0c2d75 rdf:first sg:person.07546306573.76
163 rdf:rest Ne1d8a0ff93ed42ba985de280210abc59
164 N5a287b1f975543f0ae33faa927f6a832 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
165 schema:name Sleep Aids, Pharmaceutical
166 rdf:type schema:DefinedTerm
167 N70690f84096c4ae6af0940cc6d42805c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
168 schema:name Aged
169 rdf:type schema:DefinedTerm
170 N79de78b8f5b244049456f0ae4b2a372d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
171 schema:name Middle Aged
172 rdf:type schema:DefinedTerm
173 N7e319f445f7b4b8992a700d104ce5c39 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
174 schema:name Triazoles
175 rdf:type schema:DefinedTerm
176 N7fa924a4f00a49e898c44c3dfb0ae0c0 schema:name Springer Nature - SN SciGraph project
177 rdf:type schema:Organization
178 N92b3add168f14889ab6c5e35371f1451 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Japan
180 rdf:type schema:DefinedTerm
181 N962664f213c149ecbd9ac65e6251515a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
182 schema:name Young Adult
183 rdf:type schema:DefinedTerm
184 N96c0541326c649a7b5dc0d00f73e1362 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
185 schema:name Female
186 rdf:type schema:DefinedTerm
187 N986b268aad8e49a39b9789a538ccf7c2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Sleep Latency
189 rdf:type schema:DefinedTerm
190 N9b207271b7f0421689ece24329dc219a schema:volumeNumber 19
191 rdf:type schema:PublicationVolume
192 Na4c522335eef4d958960110caef947b1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
193 schema:name Male
194 rdf:type schema:DefinedTerm
195 Ndc282c28289e46adada8d9fbcdb4f607 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
196 schema:name Adult
197 rdf:type schema:DefinedTerm
198 Ndfc1dd7a1e444e8e9395d92aa880f621 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Drug Utilization Review
200 rdf:type schema:DefinedTerm
201 Ne0de215c486c464698d437aa7b950f48 schema:name dimensions_id
202 schema:value pub.1110639167
203 rdf:type schema:PropertyValue
204 Ne1d8a0ff93ed42ba985de280210abc59 rdf:first sg:person.013165150250.11
205 rdf:rest N39353125415947d0aa8e387f1bb86fcd
206 Ne3c2ef4ee0d14096b3e57e5b4c99bb32 schema:issueNumber 1
207 rdf:type schema:PublicationIssue
208 Nec4c3d96086c45119972c2713b4f3fcc rdf:first sg:person.014560111250.07
209 rdf:rest N54ab11c585a445d3bed90d066e0c2d75
210 Nec5ded7d897e4149846dd94faa3e0dc5 rdf:first sg:person.010245361450.00
211 rdf:rest rdf:nil
212 Nf0c35db6c7c142749f2437aa1d28c3b2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Humans
214 rdf:type schema:DefinedTerm
215 Nfb973909dd0c4f658e58b39895d181e7 schema:name doi
216 schema:value 10.1007/s40268-018-0256-6
217 rdf:type schema:PropertyValue
218 Nfdd560171469486eb4a5350138f002fa rdf:first sg:person.016060561550.39
219 rdf:rest Nec5ded7d897e4149846dd94faa3e0dc5
220 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
221 schema:name Medical and Health Sciences
222 rdf:type schema:DefinedTerm
223 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
224 schema:name Clinical Sciences
225 rdf:type schema:DefinedTerm
226 anzsrc-for:1117 schema:inDefinedTermSet anzsrc-for:
227 schema:name Public Health and Health Services
228 rdf:type schema:DefinedTerm
229 sg:journal.1020803 schema:issn 1174-5886
230 1179-6901
231 schema:name Drugs in R&D
232 schema:publisher Springer Nature
233 rdf:type schema:Periodical
234 sg:person.010245361450.00 schema:affiliation grid-institutes:grid.473495.8
235 schema:familyName Hara
236 schema:givenName Mitsuyoshi
237 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010245361450.00
238 rdf:type schema:Person
239 sg:person.013165150250.11 schema:affiliation grid-institutes:grid.473495.8
240 schema:familyName Miyazaki
241 schema:givenName Makoto
242 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013165150250.11
243 rdf:type schema:Person
244 sg:person.014560111250.07 schema:affiliation grid-institutes:grid.473495.8
245 schema:familyName Asai
246 schema:givenName Yuko
247 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.014560111250.07
248 rdf:type schema:Person
249 sg:person.016060561550.39 schema:affiliation grid-institutes:grid.473495.8
250 schema:familyName Maeda
251 schema:givenName Yoshikazu
252 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016060561550.39
253 rdf:type schema:Person
254 sg:person.016153052250.08 schema:affiliation grid-institutes:grid.473495.8
255 schema:familyName Iwakura
256 schema:givenName Mika
257 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.016153052250.08
258 rdf:type schema:Person
259 sg:person.07546306573.76 schema:affiliation grid-institutes:grid.473495.8
260 schema:familyName Sano
261 schema:givenName Hideki
262 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07546306573.76
263 rdf:type schema:Person
264 grid-institutes:grid.473495.8 schema:alternateName Neuropsychiatry, Medical Information, Medical Affairs, MSD K.K., Tokyo, Japan
265 Pharmacovigilance, MSD K.K., Tokyo, Japan
266 schema:name Neuropsychiatry, Medical Information, Medical Affairs, MSD K.K., Tokyo, Japan
267 Pharmacovigilance, MSD K.K., Tokyo, Japan
268 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...